Zimmer Biomet (NYSE: ZBH) shares are up today on second-quarter results that beat the consensus forecast.
Shares of ZBH were up more than 6% to $97.44 apiece by midday trading today.
The Warsaw, Indiana–based orthopedic device giant reported profits of $152.8 million. That equals 77¢ per share on sales of $2.08 billion for the three months ended June 30, 2025.
Zimmer Biomet — one of the largest orthopedic device companies in the world — recorded a 37.1% bottom-line slide on a sales increase of 7%.
Adjusted to exclude one-time items, earnings per share came in at $2.07. That landed 9¢ ahead of estimates on Wall Street. Sales also topped expectations as experts forecast $2.06 billion in revenue.
For more on Zimmer Biomet and the orthopedic device space, see our recent special report.
Zimmer Biomet saw growth across several businesses, including its S.E.T. (Sports Medicine, Extremities, Trauma, Craniomaxillofacial and Thoracic) business, which recorded $550.6 million in sales for 17.3% growth year over year. Hips (5.8%) and Knees (3.1%) also saw increases from the same period a year ago.
“Our team delivered another solid quarter of growth, as our robust new product cycle drove significant acceleration in our U.S. Hips and Knees portfolios and continued strong growth in our global S.E.T. business,” said Ivan Tornos, chair, president and CEO of Zimmer Biomet. “We are excited about the early customer enthusiasm and adoption for our broad new product portfolio, which we believe will continue to fuel our growth through 2025 and beyond. Customer-centric innovation like this is central to our long-term strategy, and the recent agreement to acquire Monogram Technologies not only marks a bold step forward in surgical robotics but also exemplifies our commitment to addressing the most meaningful challenges in healthcare.”
Zimmer Biomet expects adjusted EPS to range between $8.10 and $8.30 for the full year, rising from a previous range of $7.90-$8.10. It narrowed its sales guidance from between 5.7% to 8.2% to between 6.7% and 7.7%.
The analysts’ take
BTIG analysts Ryan Zimmerman and Iseult McMahon maintain a “Buy” rating for Zimmer Biomet. They wrote that organic growth came in “better than feared” while the Paragon Technologies business remains steady.
“Overall, we believe results came in better than feared as mgmt. left room open for softer organic growth in 2Q,” the analysts wrote. “3Q is off to a strong start with ZBH noting ~6%+ organic growth bolstered by OUS orders and strong procedure demand in July (consistent with SYK commentary). As ZBH moves into 2H25 it faces an easier comp with added contributions from new products and recent M&A that we believe position it for improved growth in 2H25 coupled with improving OMs.”
